# Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC

> **NCT05546879** · PHASE1 · SUSPENDED · sponsor: **University Hospital, Grenoble** · enrollment: 43 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** NP137
- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05546879
- **Lead sponsor:** University Hospital, Grenoble
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2023-03-15
- **Primary completion:** 2026-03-15
- **Final completion:** 2027-03-15
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** Number of patients achieved and treatment ongoing
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05546879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05546879, "Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05546879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*